HBW Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech Losing Its Legs? Avastin Study Proposal Undercut By Feasibility, Scientific Concerns

Executive Summary

Genentech’s proposal to run a new confirmatory trial of Avastin (bevacizumab) while the first-line metastatic breast cancer claim remains on label was undermined by practical considerations raised at the June 28-29 hearing on CDER's proposal to withdraw the indication.
Advertisement

Related Content

Genentech Restricts Population In Last-Ditch Bid To Keep Avastin’s Breast Cancer Claim
Quality-Of-Life Data Take On Added Significance With Avastin Debate
Avastin Debate Could Provide Clarity On Use Of Progression-Free Survival Endpoints
Women's Right To Choose Avastin Debated During House PDUFA Hearing
Avastin Debate Could Provide Clarity On Use Of Progression-Free Survival Endpoints
Avastin’s Breast Cancer Claim: Will FDA’s Hamburg Take A Middle Road?
Avastin’s Breast Cancer Claim: Will FDA’s Hamburg Take A Middle Road?
New Avastin Breast Cancer Study Proposal Not Enough To Save Current Claim, ODAC Concludes
CDER Attacks Genentech's Plans For New Confirmatory Trial At Avastin Hearing
Genentech Banking On Biomarker Data To Save Avastin In Breast Cancer

Topics

Advertisement
UsernamePublicRestriction

Register

PS053573

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel